



10 February 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")

Speculation regarding a potential fundraising

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes today's online speculation and confirms that it has conditional investor support for an equity fundraising at 5p per share and that it is considering undertaking a share placing to raise approximately £5m with an accompanying open offer to raise up to a further £2m.

Any such fundraising would however be conditional upon certain other corporate actions currently being explored by the Group and, accordingly, there is no certainty at this time that any such fundraise will proceed.

A further announcement will be made in due course as necessary.

Contacts:

Omega Diagnostics Group PLC

Jag Grewal, Chief Executive Officer
Chris Lea, Chief Financial Officer

www.omegadx.com

via Walbrook PR

finnCap Ltd

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)
Alice Lane/ Charlotte Sutcliffe (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Applegarth
Sam Allen

Tel: 020 7933 8780 or omega@walbrookpr.com

Mob: 07980 541 893

Mob: 07584 391 303

Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com